The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2017A Novel Role for Galectin Proteins in the Neuronal Response to Alpha-synuclein Invasion
Study Rationale:
Galectins proteins (proteins that bind sugar molecules) mediate the cellular response to endocytic (transfer of molecules to cells) vesicles (storage sacks) ruptured by amyloid... -
Research Grant, 2017Standard Operating Procedures for Alpha-synuclein Analysis in Biological Fluids Using a Colorimetric Immunoassay (SYN-SOP)
Study Rationale:
The alpha-synuclein protein accumulates in structures called Lewy bodies in the brains of those with Parkinson's disease (PD). These protein clumps are considered to be one of the key... -
Target Advancement Program, 2017Toll-like Receptor Inhibition to Block Alpha-synuclein-induced Pro-inflammatory Signaling and Cytokine Release
Study Rationale:
Synucleinopathies, including Parkinson's disease (PD), are a family of central nervous system (CNS) degenerative disorders characterized by alpha-synuclein protein-containing... -
Improved Biomarkers and Clinical Outcome Measures, 2017Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in Parkinson's Disease
Study Rationale:
This project will test a new idea for measuring the severity of Parkinson's disease (PD). The brain acts as if it can store each dose of levodopa (L DOPA) for a short period of time... -
Research Grant, 2017Improving Participation in Clinical Trials in Individuals with Atypical Parkinsonian Syndromes through Virtual Research Visits (ImPaCT-Atypical)
Objective/Rationale:
The Michael J. Fox Foundation's Fox Trial Finder is designed to facilitate and increase the participation of individuals with Parkinson's disease (PD) and degenerative... -
Therapeutic Pipeline Program, 2017Advancing Neuroprotective Protein Regulators Toward the Clinical Candidate Phase
Study Rationale:
Addex Pharmaceuticals has developed drug discovery tools that can be used to screen its small molecule compound library for positive allosteric modulators (protein regulators) of TrkB...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.